<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994158</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS 261989</org_study_id>
    <nct_id>NCT04994158</nct_id>
  </id_info>
  <brief_title>MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis</brief_title>
  <acronym>MASCOT-R</acronym>
  <official_title>Myeloproliferative Neoplasms Associated SplanChnic Vein Thrombosis: Mascot Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Free Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A registry of UK patients diagnosed to have splanchnic vein thrombosis and myeloproliferative&#xD;
      neoplasm, including isolated mutation of JAK2V617f. The purpose of the registry is to&#xD;
      understand outcomes, treatment variations and data to inform and enable future clinical trial&#xD;
      design and facilitate regulatory approval decision-making.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal,&#xD;
      superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in&#xD;
      the general population based on autopsy reports. However, 40-50% of patients with hepatic&#xD;
      vein thrombosis and about 25-30% of patients with PVT have an underlying myeloproliferative&#xD;
      disease that is the cause of the thrombosis. Although some data on MPN-SVT have been&#xD;
      published from European registries, the lack of sufficient clinical and scientific data in&#xD;
      these patients has led to variation in treatment patterns with regard to timing, choice and&#xD;
      duration of anticoagulation, the use of cytotoxic or biologic agents and interventions with&#xD;
      thrombolysis and stenting with TIPSS in the acute stage. Data on the patterns of treatment of&#xD;
      these patients in U.K and their outcomes with regard to morbidity and mortality are lacking.&#xD;
      Availability of such data in U.K. will lead to the design of good quality prospective&#xD;
      interventional studies.&#xD;
&#xD;
      PROJECT DESIGN This registry is designed for longitudinal real-world data collection on UK&#xD;
      patients with MPN-SVT who are managed at tertiary liver centres in U.K. A pre-defined data&#xD;
      set, built by a committee of specialist clinicians from the Mascot registry investigators&#xD;
      will be collected and entered into the electronic web-based database built by Dendrite&#xD;
      Clinical Systems Ltd.&#xD;
&#xD;
      The data captured includes demographic information linked to the NHS number, which will&#xD;
      enable linked-anonymous data accrual and analysis as well as correlation with the Systemic&#xD;
      Anti-Cancer Therapy Data Set (SACT) via the National Cancer Registration and Analysis Service&#xD;
      (NCRAS) and Cancer Drug Fund (CDF) database. It will also allow interrogation of the national&#xD;
      registries for stroke (SSNAP) and cardiac surgery (NACSA) as co-morbidities involving&#xD;
      arterial circulation are prevalent in 30% of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2034</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2034</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>transformation of MPN</measure>
    <time_frame>5 years</time_frame>
    <description>transformation to Myelofibrosis or leukaemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression of liver disease</measure>
    <time_frame>5 years</time_frame>
    <description>progression of liver disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>thrombosis events</measure>
    <time_frame>5 years</time_frame>
    <description>new or recurrent or improvement of thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>haemorrhage events</measure>
    <time_frame>5 years</time_frame>
    <description>haemorrhage</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Splanchnic Vein Thrombosis</condition>
  <condition>JAK2 V617</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drugs, procedures</intervention_name>
    <description>standard of care only. non interventional registry.</description>
    <other_name>cytoreductive drugs, anticoagulation drugs</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MPN of any category and splanchnic vein thrombosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Myeloproliferative neoplasm (MPN, WHO 2008, WHO 2016, BCSH) and splanchnic vein&#xD;
             thrombosis&#xD;
&#xD;
          -  Isolated Jak2v617f allele and splanchnic vein thrombosis&#xD;
&#xD;
          -  MPN and portal cavernoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Free London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Free Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Mallika Sekhar</investigator_full_name>
    <investigator_title>Consultant Haematologist</investigator_title>
  </responsible_party>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data of identifiable nature will not be shared. Post analysis data will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

